Abstract Number: 1439 • ACR Convergence 2024
Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…Abstract Number: 1480 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Background/Purpose: In the phase 3 BE MOBILE 1 and 2 studies, bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits interleukin (IL)-17F in addition to IL-17A,…Abstract Number: 1868 • ACR Convergence 2024
Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis
Background/Purpose: Current axial spondyloarthritis (axSpA) guidelines do not provide recommendations for opioids in pain management. Opioid use is common in axSpA, despite widespread uptake of…Abstract Number: 1891 • ACR Convergence 2024
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…Abstract Number: 1892 • ACR Convergence 2024
Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis
Background/Purpose: Patients with axial spondyloarthritis (axSpA) bear a substantial burden of chronic opioid use despite the availability of effective treatments like tumor necrosis factor inhibitors…Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…Abstract Number: 1012 • ACR Convergence 2024
Disparities in Time to Diagnosis for Radiographic Axial Spondyloarthritis
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA; formerly ankylosing spondylitis) has an average diagnostic delay of 7 years, which can lead to a diminished quality of life…Abstract Number: 0437 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…Abstract Number: 0510 • ACR Convergence 2023
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In the phase 3 studies BE MOBILE 1 and…Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…Abstract Number: 0739 • ACR Convergence 2023
Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…Abstract Number: 0841 • ACR Convergence 2023
Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis
Background/Purpose: In the United States (US), the diagnosis of axial spondyloarthritis (axSpA) continues to be delayed by an average of 10 years from symptom onset.…Abstract Number: 1386 • ACR Convergence 2023
Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis
Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…
Advanced Search Results
-
Title
---